Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (100) 100
cystic fibrosis (97) 97
respiratory system (86) 86
index medicus (83) 83
female (57) 57
male (53) 53
adult (48) 48
pulmonary/respiratory (37) 37
cystic fibrosis - drug therapy (29) 29
adolescent (28) 28
critical care medicine (26) 26
child (25) 25
administration, inhalation (24) 24
cystic fibrosis - complications (24) 24
care and treatment (23) 23
abridged index medicus (22) 22
cystic fibrosis - physiopathology (22) 22
treatment outcome (21) 21
anti-bacterial agents - administration & dosage (20) 20
middle aged (20) 20
antibiotics (19) 19
children (19) 19
cystic fibrosis - therapy (19) 19
pseudomonas-aeruginosa (19) 19
anti-bacterial agents - therapeutic use (17) 17
pseudomonas infections - drug therapy (15) 15
analysis (14) 14
article (14) 14
cystic fibrosis - microbiology (14) 14
disease (14) 14
clinical trials (13) 13
pseudomonas aeruginosa (13) 13
pseudomonas aeruginosa - drug effects (13) 13
pseudomonas-aeruginosa infection (13) 13
time factors (13) 13
double-blind method (12) 12
young adult (12) 12
cystic fibrosis - diagnosis (11) 11
cystic fibrosis - genetics (11) 11
disease progression (11) 11
cystic fibrosis transmembrane conductance regulator - genetics (10) 10
efficacy (10) 10
guidelines (10) 10
lung transplantation (10) 10
lung-function (10) 10
mutation (10) 10
pediatrics (10) 10
quality of life (10) 10
quality-of-life (10) 10
respiratory function tests (10) 10
respiratory tract infections - drug therapy (10) 10
bronchiectasis (9) 9
diagnosis (9) 9
fev1 (9) 9
forced expiratory volume (9) 9
inhaled tobramycin (9) 9
pharmacology & pharmacy (9) 9
pulmonary-function (9) 9
risk factors (9) 9
adults (8) 8
allergic bronchopulmonary aspergillosis (8) 8
chronic disease (8) 8
double-blind (8) 8
follow-up studies (8) 8
health aspects (8) 8
inhaled aztreonam lysine (8) 8
ivacaftor (8) 8
medical colleges (8) 8
medical research (8) 8
medicine, general & internal (8) 8
microbiology (8) 8
pediatrics, perinatology, and child health (8) 8
pulmonary and respiratory medicine (8) 8
pulmonary exacerbation (8) 8
tobramycin (8) 8
cardiac & cardiovascular systems (7) 7
cystic-fibrosis (7) 7
drug therapy (7) 7
exacerbations (7) 7
infections (7) 7
lung - physiopathology (7) 7
management (7) 7
prospective studies (7) 7
pulmonary exacerbations (7) 7
retrospective studies (7) 7
safety (7) 7
adolescents (6) 6
aerosols (6) 6
airway pseudomonas (6) 6
complications (6) 6
controlled-trial (6) 6
exercise (6) 6
forced expiratory volume - drug effects (6) 6
gene (6) 6
health (6) 6
hemoptysis (6) 6
infant (6) 6
infection (6) 6
lung-disease (6) 6
patients (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pulmonary Complications of Cystic Fibrosis
by Garcia, Bryan and Flume, Patrick A
Seminars in Respiratory and Critical Care Medicine, ISSN 1069-3424, 10/2019
Abstract Cystic fibrosis (CF) lung disease is characterized by the development of progressive bronchiectasis and impaired lung function with severe airflow... 
Review Article
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Clinical care for cystic fibrosis: preparing for the future now
by Konstan, Michael W and Flume, Patrick A
The Lancet Respiratory Medicine, ISSN 2213-2600, 09/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Impact of a Reduction in Susceptibility Testing for Pseudomonas aeruginosa in a Cystic Fibrosis Program
by Ponce, Mario C and Svendsen, Erik and Steed, Lisa and Flume, Patrick A
American journal of respiratory and critical care medicine, ISSN 1073-449X, 08/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The study of CFTR modulators in the very young
by Flume, Patrick A
The Lancet Respiratory Medicine, ISSN 2213-2600, 04/2019, Volume 7, Issue 4, pp. 287 - 289
RESPIRATORY SYSTEM | DISEASE | AGED 6-11 YEARS | CYSTIC-FIBROSIS | LUMACAFTOR/IVACAFTOR | POTENTIATOR | CHILDREN | CRITICAL CARE MEDICINE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Mycobacterial Disease: Evolving Concepts
by Flume, Patrick A and Winthrop, Kevin L
Seminars in Respiratory and Critical Care Medicine, ISSN 1069-3424, 06/2018, Volume 39, Issue 3, pp. 269 - 269
Preface | Latent Tuberculosis - therapy | Humans | Latent Tuberculosis - epidemiology | Mycobacterium Infections, Nontuberculous - therapy | Mycobacterium Infections, Nontuberculous - epidemiology | Latent Tuberculosis - diagnosis | Mycobacterium Infections, Nontuberculous - diagnosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity
by Flume, Patrick A and Chalmers, James D and Olivier, Kenneth N
The Lancet, ISSN 0140-6736, 09/2018, Volume 392, Issue 10150, pp. 880 - 890
Bronchiectasis is characterised by pathological dilation of the airways. More specifically, the radiographic demonstration of airway enlargement is the common... 
HYPER-IGE SYNDROME | PRIMARY CILIARY DYSKINESIA | ADULT PATIENTS | MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | CYSTIC FIBROSIS BRONCHIECTASIS | NONTUBERCULOUS MYCOBACTERIAL INFECTION | POLYCYSTIC KIDNEY-DISEASE | X-LINKED AGAMMAGLOBULINEMIA | ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS | INDEPENDENT RISK-FACTOR | Bronchiectasis - genetics | Genetic Predisposition to Disease | Microbiota | Humans | Autoimmune Diseases - complications | Immunocompetence | Mutation | Bronchiectasis - microbiology | Cystic Fibrosis - complications | Bronchiectasis - physiopathology | Disease Progression | Bronchiectasis - etiology | Medical colleges | Cystic fibrosis | Genetics | Bronchiectasis | Physicians | Microbiomes | Clinical trials | Infections | Respiratory tract | Heterogeneity | Chronic obstructive pulmonary disease | Age | Enlargement | Medical personnel | Pathogens | Medical research | Phenotypes | Bacterial infections | Research & development--R&D | Patients | Asthma | Inflammatory bowel disease | Antibiotics | Fibrosis | Biomarkers | Kidney diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
by Wainwright, Claire E and Elborn, J. Stuart and Ramsey, Bonnie W and Marigowda, Gautham and Huang, Xiaohong and Cipolli, Marco and Colombo, Carla and Davies, Jane C and De Boeck, Kris and Flume, Patrick A and Konstan, Michael W and McColley, Susanna A and McCoy, Karen and McKone, Edward F and Munck, Anne and Ratjen, Felix and Rowe, Steven M and Waltz, David and Boyle, Michael P and TRAFFIC Study Grp and TRANSPORT Study Grp and TRANSPORT Study Group and TRAFFIC Study Group
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 220 - 231
This study identified a new combination therapy for patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. Treatment with ivacaftor, a CFTR... 
TRANSMEMBRANE CONDUCTANCE REGULATOR | MEDICINE, GENERAL & INTERNAL | POTENTIATOR IVACAFTOR | IN-VITRO | EFFICACY | SAFETY | PSEUDOMONAS-AERUGINOSA | STABILITY | MUTATION | F508DEL-CFTR | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Aminopyridines - adverse effects | Hospitalization - statistics & numerical data | Male | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Young Adult | Quinolones - adverse effects | Adult | Benzodioxoles - adverse effects | Female | Drug Therapy, Combination | Child | Aminopyridines - administration & dosage | Double-Blind Method | Homozygote | Quinolones - administration & dosage | Cystic Fibrosis - genetics | Adolescent | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Mutation | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Clinical trials | Cystic fibrosis | Care and treatment | Ivacaftor | Usage | Dosage and administration | Studies | Proteins | Intravenous administration | Antibiotics | Conductance | Drug therapy | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Introduction
by Patrick A. Flume
Respiratory Medicine, ISSN 0954-6111, 12/2011, Volume 105, p. S2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Introduction
by Flume, Patrick A
Respiratory Medicine, ISSN 0954-6111, 12/2011, Volume 105, p. S2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Rheumatoid arthritis-associated bronchiectasis – Authors' reply
by Flume, Patrick A and Chalmers, James D and Olivier, Kenneth N
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10185, pp. 2036 - 2036
Fees & charges | Bacterial infections | Research & development--R&D | Rheumatoid arthritis | Cystic fibrosis | Arthritis | Bronchiectasis | Pharmaceutical industry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text News
by Flume, Patrick
Journal of Cystic Fibrosis, ISSN 1569-1993, 01/2016, Volume 15, Issue 1, pp. 8 - 9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text News
by Flume, Patrick
Journal of Cystic Fibrosis, ISSN 1569-1993, 01/2016, Volume 15, Issue 1, p. 8
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text News
by Flume, Patrick
Journal of Cystic Fibrosis, ISSN 1569-1993, 01/2016, Volume 15, Issue 1, pp. 8 - 9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
by Flume, Patrick A., MD
Journal of Cystic Fibrosis, ISSN 1569-1993, 2016, Volume 15, Issue 2, pp. 139 - 140
Pulmonary/Respiratory | Nontuberculous Mycobacteria | Societies, Medical | Mycobacterium Infections, Nontuberculous - microbiology | United States | Europe | Humans | Mycobacterium Infections, Nontuberculous - therapy | Cystic Fibrosis - complications | Consensus | Mycobacterium Infections, Nontuberculous - complications | Cystic fibrosis | Tuberculosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Introduction
by Flume, Patrick A
Respiratory Medicine, ISSN 0954-6111, 2011, Volume 105, pp. S2 - S2
Antibiotic alternation | Cystic fibrosis | Aerosolized antibiotics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Introduction
by Flume, Patrick A
Respiratory Medicine, ISSN 0954-6111, 2011, Volume 105, Issue 2, p. S2
Antibiotic alternation | Cystic fibrosis | Aerosolized antibiotics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Introduction
by Flume, Patrick A
Respiratory Medicine, ISSN 0954-6111, 2011, Volume 105, pp. S2 - S2
Pulmonary/Respiratory
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text News
by Flume, Patrick
Journal of Cystic Fibrosis, ISSN 1569-1993, 2015, Volume 15, Issue 1, pp. 8 - 9
Pulmonary/Respiratory
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Aerosolized Antibiotics for Patients with Bronchiectasis
by Nadig, Tejaswi R and Nadig, Tejaswi R and Flume, Patrick A and Flume, Patrick A
American journal of respiratory and critical care medicine, ISSN 1073-449X, 04/2016, Volume 193, Issue 7, pp. 808 - 810
INFECTION | RESPIRATORY SYSTEM | CYSTIC FIBROSIS BRONCHIECTASIS | CRITICAL CARE MEDICINE | Severity of Illness Index | Bronchiectasis - drug therapy | Outcome Assessment (Health Care) | Humans | Middle Aged | Administration, Inhalation | Male | Tomography, X-Ray Computed | Disease Progression | Bronchiectasis - pathology | Anti-Bacterial Agents - therapeutic use | Phenotype | Bronchiectasis - diagnostic imaging | Female | Retrospective Studies | Anti-Bacterial Agents - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Clinical applications of pulmonary delivery of antibiotics
by Flume, Patrick A and VanDevanter, Donald R
Advanced Drug Delivery Reviews, ISSN 0169-409X, 05/2015, Volume 85, pp. 1 - 6
The treatment of infection typically involves administration of antibiotics by a systemic route, such as intravenous or oral. However, pulmonary infections can... 
Cystic fibrosis | Bronchiectasis | Pneumocystis | Aerosol | Mycobacteria | Inhaled antibiotics | INHALED TOBRAMYCIN | RANDOMIZED CONTROLLED-TRIAL | VENTILATED PATIENTS | NEBULIZED GENTAMICIN | PSEUDOMONAS-AERUGINOSA INFECTION | CYSTIC FIBROSIS BRONCHIECTASIS | AEROSOLIZED ANTIBIOTICS | PHARMACOLOGY & PHARMACY | PNEUMOCYSTIS-CARINII PNEUMONIA | QUALITY-OF-LIFE | YOUNG-CHILDREN | Pneumonia, Pneumocystis - drug therapy | Cystic Fibrosis - microbiology | Pseudomonas Infections - drug therapy | Humans | Administration, Inhalation | Pseudomonas aeruginosa - drug effects | Pseudomonas Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Mycobacterium Infections - drug therapy | Pneumocystis carinii - drug effects | Aerosols | Mycobacterium Infections - microbiology | Pneumonia, Pneumocystis - microbiology | Anti-Bacterial Agents - administration & dosage | Cystic Fibrosis - drug therapy | Drugs | Drug delivery systems | Antibiotics | Vehicles | inhaled antibiotics | bronchiectasis | mycobacteria | cystic fibrosis | aerosol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.